Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study.
Addiction
Aripiprazole
Clozapine
Cognition
Negative symptoms
Pregnancy
Schizophrenia
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
28 05 2022
28 05 2022
Historique:
received:
24
02
2022
accepted:
16
05
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Aripiprazole is a second-generation antipsychotic, efficacious in patients with schizophrenia during acute episodes. Due to its pharmacological profile, aripiprazole may be of interest in patients with specific clinical profiles who have not been studied extensively in randomised clinical trials. To capture experience with aripiprazole in everyday psychiatric practice using the Delphi method in order to inform decision-making on the use of aripiprazole for the treatment of patients with schizophrenia in clinical situations where robust evidence from clinical trials is lacking. The scope of the survey was defined as the management of schizophrenia in adults. A systematic literature review was performed to identify the different clinical situations in which aripiprazole has been studied, and to describe the level of clinical evidence. Clinical profiles to include in the Delphi survey were selected if there was a clear interest in terms of medical need but uncertainty over the efficacy of aripiprazole. For each clinical profile retained, five to seven specific statements were generated and included in a questionnaire. The final 41-item questionnaire was proposed to a panel of 406 French psychiatrists with experience in the treatment of schizophrenia. Panellists rated their level of agreement using a Likert scale. A second round of voting on eleven items was organised to clarify points for which a consensus was not obtained in the first round. Five clinical profiles were identified in the literature review (persistent negative symptoms, pregnancy, cognitive dysfunction, addictive comorbidity and clozapine resistance). Sixty-two psychiatrists participated in the first round of the Delphi survey and 33 in the second round. A consensus was obtained for 11 out of 41 items in the first round and for 9/11 items in the second round. According to the panellists' clinical experience, aripiprazole can be used as maintenance treatment for pregnant women, is relevant to preserve cognitive function and can be considered an option in patients with a comorbid addictive disorder or with persistent negative symptoms. These findings may help physicians in choosing relevant ways to use aripiprazole and highlight areas where more research is needed to widen the evidence base.
Sections du résumé
BACKGROUND
Aripiprazole is a second-generation antipsychotic, efficacious in patients with schizophrenia during acute episodes. Due to its pharmacological profile, aripiprazole may be of interest in patients with specific clinical profiles who have not been studied extensively in randomised clinical trials.
OBJECTIVES
To capture experience with aripiprazole in everyday psychiatric practice using the Delphi method in order to inform decision-making on the use of aripiprazole for the treatment of patients with schizophrenia in clinical situations where robust evidence from clinical trials is lacking.
METHODS
The scope of the survey was defined as the management of schizophrenia in adults. A systematic literature review was performed to identify the different clinical situations in which aripiprazole has been studied, and to describe the level of clinical evidence. Clinical profiles to include in the Delphi survey were selected if there was a clear interest in terms of medical need but uncertainty over the efficacy of aripiprazole. For each clinical profile retained, five to seven specific statements were generated and included in a questionnaire. The final 41-item questionnaire was proposed to a panel of 406 French psychiatrists with experience in the treatment of schizophrenia. Panellists rated their level of agreement using a Likert scale. A second round of voting on eleven items was organised to clarify points for which a consensus was not obtained in the first round.
RESULTS
Five clinical profiles were identified in the literature review (persistent negative symptoms, pregnancy, cognitive dysfunction, addictive comorbidity and clozapine resistance). Sixty-two psychiatrists participated in the first round of the Delphi survey and 33 in the second round. A consensus was obtained for 11 out of 41 items in the first round and for 9/11 items in the second round. According to the panellists' clinical experience, aripiprazole can be used as maintenance treatment for pregnant women, is relevant to preserve cognitive function and can be considered an option in patients with a comorbid addictive disorder or with persistent negative symptoms.
CONCLUSION
These findings may help physicians in choosing relevant ways to use aripiprazole and highlight areas where more research is needed to widen the evidence base.
Identifiants
pubmed: 35643542
doi: 10.1186/s12888-022-04008-9
pii: 10.1186/s12888-022-04008-9
pmc: PMC9142729
doi:
Substances chimiques
Dopamine Agonists
0
Aripiprazole
82VFR53I78
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
364Informations de copyright
© 2022. The Author(s).
Références
Curr Pharm Des. 2010;16(5):488-501
pubmed: 19909227
World J Biol Psychiatry. 2012 Jul;13(5):318-78
pubmed: 22834451
Am J Psychiatry. 2018 Jun 1;175(6):564-574
pubmed: 29730938
Drugs Real World Outcomes. 2020 Mar;7(1):75-83
pubmed: 32026379
Arch Gen Psychiatry. 2007 Jun;64(6):633-47
pubmed: 17548746
Lancet. 2016 Jul 2;388(10039):86-97
pubmed: 26777917
J Affect Disord. 2018 Oct 1;238:593-596
pubmed: 29957476
Clin Neuropharmacol. 2010 May;33(3):121-5
pubmed: 20502130
Schizophr Bull. 1999;25(2):233-55
pubmed: 10416729
Cochrane Database Syst Rev. 2017 Mar 23;3:CD006324
pubmed: 28333365
J Psychopharmacol. 2012 Jun;26(6):806-12
pubmed: 21616975
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):373-7
pubmed: 17092620
Psychopharmacology (Berl). 2006 Aug;187(3):312-20
pubmed: 16810506
Curr Med Res Opin. 2007 Mar;23(3):467-75
pubmed: 17355728
Neuropsychiatr Dis Treat. 2015 Oct 13;11:2635-47
pubmed: 26508859
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):161-8
pubmed: 21047544
Arch Gen Psychiatry. 2012 Jul;69(7):715-21
pubmed: 22752236
Aust N Z J Psychiatry. 2018 Aug;52(8):751-767
pubmed: 29732913
Nord J Psychiatry. 2014 Apr;68(3):219-24
pubmed: 23795862
J Clin Psychopharmacol. 2014 Oct;34(5):637-41
pubmed: 24949701
CNS Spectr. 2021 Oct;26(5):444-445
pubmed: 32594931
Eur J Clin Pharmacol. 2014 Feb;70(2):127-34
pubmed: 24145817
J Clin Psychopharmacol. 2011 Jun;31(3):377-9
pubmed: 21532364
Nat Rev Drug Discov. 2013 Mar;12(3):205-16
pubmed: 23411724
Acta Psychiatr Scand. 2020 Dec;142(6):456-466
pubmed: 32869278
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Arch Womens Ment Health. 2008 Jul;11(3):249-50
pubmed: 18581041
Biol Psychiatry. 2017 Jan 1;81(1):78-85
pubmed: 27832841
J Clin Psychopharmacol. 2013 Jun;33(3):319-28
pubmed: 23609378
J Clin Psychopharmacol. 2011 Aug;31(4):531-2
pubmed: 21720228
J Clin Psychopharmacol. 2019 Sep/Oct;39(5):508-509
pubmed: 31433346
Psychiatry Clin Neurosci. 2014 Jul;68(7):582-3
pubmed: 24521035
Arch Womens Ment Health. 2021 Aug;24(4):659-667
pubmed: 33710399
BMJ. 1996 Jan 13;312(7023):71-2
pubmed: 8555924
Schizophr Bull. 2015 Jul;41(4):892-9
pubmed: 25528757
Aust N Z J Obstet Gynaecol. 2020 Feb;60(1):63-69
pubmed: 31141172
Clin Neuropharmacol. 2006 Jan-Feb;29(1):28-33
pubmed: 16518132
Eur Psychiatry. 2021 Jan 08;64(1):e7
pubmed: 33413701
Hum Psychopharmacol. 2010 Mar;25(2):187-90
pubmed: 20033907
Lancet. 2009 Jan 3;373(9657):31-41
pubmed: 19058842
Eur J Clin Pharmacol. 2021 Nov;77(11):1737-1745
pubmed: 34100993
Psychiatr Danub. 2015 Sep;27 Suppl 1:S245-9
pubmed: 26417773
Am J Psychiatry. 2006 Mar;163(3):418-25
pubmed: 16513862
World Psychiatry. 2012 Jun;11(2):73-9
pubmed: 22654932
Eur Neuropsychopharmacol. 2014 Apr;24(4):575-84
pubmed: 24418213
J Clin Psychopharmacol. 2005 Aug;25(4):363-6
pubmed: 16012280
Schizophr Res. 2013 Nov;150(2-3):346-52
pubmed: 23938176
Encephale. 2007 May-Jun;33(3 Pt 1):332-8
pubmed: 17675931
Neuropsychiatr Dis Treat. 2018 Jun 21;14:1645-1656
pubmed: 29950846
Rev Colomb Psiquiatr (Engl Ed). 2020 Jan - Mar;49(1):15-22
pubmed: 32081203
Eval Health Prof. 2007 Dec;30(4):303-21
pubmed: 17986667
Ann Pharmacother. 2006 Mar;40(3):575
pubmed: 16467250
Aust N Z J Psychiatry. 1999 Dec;33(6):902-11
pubmed: 10619219
J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):796-8
pubmed: 16705205
Pharmacoepidemiol Drug Saf. 2015 Apr;24(4):368-80
pubmed: 25683615
Am J Psychiatry. 2000 Nov;157(11):1835-42
pubmed: 11058482
Arch Gynecol Obstet. 2011 Feb;283(2):141-7
pubmed: 20931211
Lancet. 2013 Sep 14;382(9896):951-62
pubmed: 23810019
Adv Ther. 2007 Jan-Feb;24(1):1-13
pubmed: 17526456
Psychiatry Res. 1991 Jun;37(3):297-308
pubmed: 1679950
Crit Rev Neurobiol. 2000;14(1):1-21
pubmed: 11253953
Neuropsychopharmacology. 2022 Feb;47(3):759-766
pubmed: 34750566
Schizophr Bull. 2006 Apr;32(2):214-9
pubmed: 16481659
Am J Addict. 2011 Sep-Oct;20(5):462-7
pubmed: 21838846
J Subst Abuse Treat. 2008 Jan;34(1):61-71
pubmed: 17574793
Schizophr Bull. 2007 Jul;33(4):1013-22
pubmed: 17099070
Expert Opin Drug Saf. 2014 Dec;13(12):1583-90
pubmed: 25189088
J Clin Psychopharmacol. 2010 Apr;30(2):204-5
pubmed: 20520299
Braz J Psychiatry. 2007 Sep;29(3):228-32
pubmed: 17891260
Indian J Psychol Med. 2019 Jul-Aug;41(4):323-330
pubmed: 31391664
J Med Internet Res. 2004 Sep 24;6(3):e30
pubmed: 15471756
PLoS One. 2014 Jun 16;9(6):e100069
pubmed: 24932547
Psychiatry Clin Neurosci. 2016 Jan;70(1):71-2
pubmed: 26556467
Expert Opin Investig Drugs. 2003 Apr;12(4):655-62
pubmed: 12665420
Aust N Z J Psychiatry. 2015 Oct;49(10):887-97
pubmed: 26296368
Ther Clin Risk Manag. 2014 Oct 23;10:901-4
pubmed: 25364259
Acta Psychiatr Scand. 2021 Jul;144(1):42-49
pubmed: 33650123
Dig Liver Dis. 2020 Apr;52(4):420-426
pubmed: 31734114
Am J Drug Alcohol Abuse. 2008;34(1):75-82
pubmed: 18161645
Infant Behav Dev. 2008 Sep;31(3):532-8
pubmed: 18499261
Can J Psychiatry. 2017 Nov;62(11):772-777
pubmed: 28655284
Clin Ther. 2010;32 Suppl 1:S3-20
pubmed: 20152550
Acta Psychiatr Scand. 2015 Mar;131(3):185-96
pubmed: 25597383
CNS Drugs. 2018 Apr;32(4):351-366
pubmed: 29637530
J Clin Psychopharmacol. 2013 Aug;33(4):533-7
pubmed: 23775051
Int J Environ Res Public Health. 2020 Aug 03;17(15):
pubmed: 32756418
Schizophr Res. 2001 Apr 30;49(3):253-60
pubmed: 11356586
JAMA Psychiatry. 2019 Oct 1;76(10):1052-1062
pubmed: 31365048
PLoS One. 2011;6(6):e20476
pubmed: 21694759
J Clin Psychopharmacol. 2004 Oct;24(5 Suppl 1):S1-6
pubmed: 15356414
J Psychiatr Pract. 2009 May;15(3):183-92
pubmed: 19461391
Eur Neuropsychopharmacol. 2012 Mar;22(3):165-82
pubmed: 21906915
Schizophr Bull. 2014 Mar;40 Suppl 2:S101-6
pubmed: 24562490
Eur Neuropsychopharmacol. 2019 Jan;29(1):57-65
pubmed: 30497841
Expert Opin Investig Drugs. 2007 Jun;16(6):771-5
pubmed: 17501690
Cochrane Database Syst Rev. 2014 Jan 02;(1):CD006569
pubmed: 24385408
J Clin Psychiatry. 2008 May;69(5):720-31
pubmed: 18370574
Drugs. 2006;66(11):1465-73
pubmed: 16906778
Am J Drug Alcohol Abuse. 2000 Aug;26(3):343-53
pubmed: 10976661
Eur Arch Psychiatry Clin Neurosci. 2015 Oct;265(7):567-78
pubmed: 25895634
J Clin Psychiatry. 2010 Mar;71(3):280-6
pubmed: 19895779
World Psychiatry. 2014 Oct;13(3):275-87
pubmed: 25273301
Pharmacopsychiatry. 2012 Nov;45(7):299-300
pubmed: 22648307
Psychopharmacology (Berl). 2016 Apr;233(8):1415-26
pubmed: 26900078
J Clin Psychopharmacol. 2006 Feb;26(1):101-3
pubmed: 16415723
Int J Psychiatry Clin Pract. 2015 Jun;19(2):90-8
pubmed: 25547440
Aust N Z J Psychiatry. 2011 Jun;45(6):500-1
pubmed: 21413838
J Adv Nurs. 2000 Oct;32(4):1008-15
pubmed: 11095242
World J Psychiatry. 2021 Aug 19;11(8):429-448
pubmed: 34513606
Encephale. 2018 Dec;44(6):558-564
pubmed: 30466778
JAMA Psychiatry. 2016 Sep 1;73(9):938-46
pubmed: 27540849
Schizophr Bull. 2010 May;36(3):518-44
pubmed: 18787227
Pharmacopsychiatry. 2010 Mar;43(2):50-7
pubmed: 20336597
Psychiatry Res. 2008 May 30;159(1-2):109-14
pubmed: 18329722
J Nerv Ment Dis. 2006 Mar;194(3):164-72
pubmed: 16534433
J Clin Psychopharmacol. 2013 Aug;33(4):453-62
pubmed: 23764684
Pharmacopsychiatry. 2010 Aug;43(6):234-5
pubmed: 20503152
Schizophr Res. 2017 Aug;186:55-62
pubmed: 27293137
Nat Rev Drug Discov. 2013 Jun;12(6):483
pubmed: 23681003
JAMA Psychiatry. 2014 Mar;71(3):248-54
pubmed: 24382686
Addiction. 2021 Sep;116(9):2463-2475
pubmed: 33449441
J Psychosom Obstet Gynaecol. 1998 Dec;19(4):210-7
pubmed: 9929847
BMC Pharmacol Toxicol. 2019 Aug 28;20(1):52
pubmed: 31462311
J Affect Disord. 2021 Jan 15;279:66-74
pubmed: 33039776
J Clin Psychiatry. 2021 Aug 3;82(4):
pubmed: 34352165
Schizophr Res. 2008 Mar;100(1-3):39-52
pubmed: 18191383
J Clin Epidemiol. 2014 Apr;67(4):401-9
pubmed: 24581294
CNS Spectr. 2017 Jun;22(3):273-281
pubmed: 27866497
Schizophr Bull. 1974 Winter;(11):61-9
pubmed: 4469362
World J Biol Psychiatry. 2016;17(2):86-128
pubmed: 26912127
BMC Med Res Methodol. 2014 Jun 06;14:76
pubmed: 24906492
Am J Psychiatry. 2011 May;168(5):472-85
pubmed: 21406461
Br Med J. 1980 Jan 12;280(6207):66-8
pubmed: 6101544
Expert Opin Pharmacother. 2016;17(2):231-53
pubmed: 26635059
J Clin Psychopharmacol. 2015 Oct;35(5):559-65
pubmed: 26274044
Br J Psychiatry. 1980 Oct;137:379-83
pubmed: 7448478
Int J Neuropsychopharmacol. 2007 Jun;10(3):433
pubmed: 17291382
Am J Psychiatry. 2005 Mar;162(3):495-506
pubmed: 15741466
Depress Anxiety. 2021 Apr;38(4):456-467
pubmed: 33528865
NPJ Schizophr. 2021 May 25;7(1):29
pubmed: 34035313
Ther Adv Drug Saf. 2014 Apr;5(2):100-9
pubmed: 25083265
Drug Saf. 2017 Nov;40(11):1141-1146
pubmed: 28664356
Bipolar Disord. 2006 Jun;8(3):299-300
pubmed: 16696834
Am J Psychiatry. 2016 Mar 1;173(3):263-70
pubmed: 26441156